期刊文献+

Survivin抑制剂YM155对K562细胞凋亡和自噬的影响 被引量:6

Effect of YM155 on Apoptosis and Autophagy of K562 Cells
下载PDF
导出
摘要 目的:本研究旨在探讨survivin抑制剂YM155对人慢性髓系白血病细胞株K562凋亡和自噬的影响。方法:采用不同浓度YM155处理K562细胞,用CCK-8法检测细胞增殖抑制作用,流式细胞术检测细胞凋亡率,RTPCR检测survivin、BCL-2及beclin1的mRNA表达水平,Western blot检测survivin、BCL-2、caspase-3、PARP及LC-3的蛋白表达。结果:YM155抑制K562细胞的增殖,且呈时间及剂量依赖性。随着药物浓度的升高及作用时间的延长,survivin和BCL-2的mRNA及蛋白表达水平下降,而caspase-3、PARP、beclin1及LC-3的表达水平升高。YM155联合3-MA组的LC-3和caspase-3蛋白表达水平以及K562细胞凋亡率均显著低于YM155单用组。结论:YM155通过诱导凋亡和自噬而抑制K562细胞的增殖,其自噬诱导效应与凋亡诱导效应有协同抗CML的作用。 Objective: This study was purposed to investigate the effect of YM155, a survivin inhibitor, on the apop tosis and autophagy of K562 cells. Methods: K562 cells were treated with YM155 at different concentration. Cell sur- vival was analyzed by CCK-8 assay, the cell apoptosis was detected by flow cytometry. Survivin, BCL-2 and beclinl mRNA expressions were determined by RT-PCR. Survivin, BCL-2, caspase-3, PARP and LC-3 protein expressions were assayed by Western blot. Results: YM155 inhibited the proliferation of K562 cells in a time- and dose-dependent manners. With the increasing of YM155 concentration and prolonging of action time, the expression levels of mRNA and protein of survivin and BCL-2 decreased, while the expression levels of caspase-3, PARP, beclinl and LC-3 increased. Compared with the YM155 group, the protein levels of LC-3 and caspase-3 were lower in YM155 combined with 3-MA group. Conclusion: YM155 can inhibit K562 cell proliferation by inducing apoptosis and autophagy, while autophagy induction effect can enhance its cytotoxic effect.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2015年第2期375-380,共6页 Journal of Experimental Hematology
基金 江苏省淮安市科技支撑计划(HAS2013027)
关键词 YM155 K562细胞 凋亡 自噬 SURVIVIN survivin YM155 K562 cell apoptosis autophagy
  • 相关文献

参考文献3

二级参考文献45

  • 1Miyashita T,Reed JC.Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line.Blood,1993;81(1):151-169. 被引量:1
  • 2Lowe SW,Bodis S,McClatchey A,et al.p53 statues and theefficacy of cancer therapy in vivo.Science,1994;266(5186):807-810. 被引量:1
  • 3Schmitt CA,Lowe SW.Bcl-2 mediates chemoresistance inmatched pairs of primary E(mu)-myc lymphomas in vivo.BloodCells Mol Dis,2001;27(1):206-216. 被引量:1
  • 4Schmitt CA,Rosenthal CT,Lowe SW.Genetic analysis ofchemoresistance in primary marine Lymphomas.Nat Med,2000;6(9):1029-1035. 被引量:1
  • 5Pennati M,Folini M,Zaffaroni N.Targeting survivin in cancertherapy:fulfilled promises and open questions.Carcinogenesis,2007;28(6):1133-1139. 被引量:1
  • 6CoiffierB,Lepage E,Briere J,et al.CHOP chemotherapy plusrituximab compared with CHOP alone in elderly patients withdiffuse large-B-cell lymphoma.N Engl J Med,2002;346(4):235-242. 被引量:1
  • 7Pfreundschuh M,Trumper L,Osterborg A,et al.CHOP-likechemotherapy plus rituximab versus CHOP-like chemotherapy alonein young patients with good-prognosis diffuse large-B-cell lym-phoma:a randomized controlled trial by the MabThera InternationalTrial(MInT)Group.Lancet Oncol,2006;7(5):379-391. 被引量:1
  • 8Feugier P,Van Hoof A,Sebban C,et al.Long-term results of theR-CHOP study in the treatment of elderly patients with diffuse largeB-cell lymphoma:a study by the Grouped“Etude des Lymphomasde l”Adulte.J Clin Oncol,2005;23(8):4117-4126. 被引量:1
  • 9Habermann TM,Weller EA,Morrison VA,et al.Rituximab-CHOP versus CHOP alone orwithmaintenance rituximab in olderpatients with diffuse large B-cell lymphoma.J Clin Oncol,2006;24(19):3121-3127. 被引量:1
  • 10Srinivasula SM,Ashwell JD.IAPs:what's in a name?Mol Cell,2008;30(2):123-135. 被引量:1

共引文献15

同被引文献48

引证文献6

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部